findmyKOL
Clinical trialNCT00407758CompletedPhase 2Interventional

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

SponsorGynecologic Oncology GroupEnrollment28Ovarian CancerPrimary Peritoneal Cavity Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well enzastaurin works in treating patients with persistent or recurrent ovarian epithelial cancer or primary peritoneal cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Jonsson Comprehensive Cancer Center at Ucla

    Los Angeles, California, United States

  • Rush University Medical Center

    Chicago, Illinois, United States

  • Decatur Memorial Hospital Cancer Care Institute

    Decatur, Illinois, United States

  • Evanston Northwestern Healthcare - Evanston Hospital

    Evanston, Illinois, United States

  • Hinsdale Hematology Oncology Associates

    Hinsdale, Illinois, United States

  • Ccop - Carle Cancer Center

    Urbana, Illinois, United States

  • St. Vincent Indianapolis Hospital

    Indianapolis, Indiana, United States

  • Ccop - Grand Rapids

    Grand Rapids, Michigan, United States

  • Hulston Cancer Center at Cox Medical Center South

    Springfield, Missouri, United States

  • Methodist Estabrook Cancer Center

    Omaha, Nebraska, United States

  • Blumenthal Cancer Center at Carolinas Medical Center

    Charlotte, North Carolina, United States

  • Oklahoma University Cancer Institute

    Oklahoma City, Oklahoma, United States

  • Rosenfeld Cancer Center at Abington Memorial Hospital

    Abington, Pennsylvania, United States

  • Fox Chase Cancer Center - Philadelphia

    Philadelphia, Pennsylvania, United States

  • Mcglinn Family Regional Cancer Center at Reading Hospital and Medical Center

    Reading, Pennsylvania, United States

  • University Cancer Center at University of Washington Medical Center

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Enzastaurin hydrochloride
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2006
Primary completion
1 Aug 2016
Completion
—
Last update posted
20 Mar 2019
Registered enrollment
28
Registry id
NCT00407758
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.